Tyra Biosciences, Inc.
NASDAQ:TYRABiotechnology
-$0.72 today
- Market cap
- $1.35B
- Beta
- 0.75
- P/E (TTM)
- -13.4
- EPS (TTM)
- -$2.12
Volume 0.47M
Average 0.96M
TYRA Total Non-current Liabilities
All obligations due after more than one year.
Tyra Biosciences, Inc.NASDAQ: TYRA
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities falls 8.5% from a year ago
Total non-current liabilities stood at $5.21M at the end of Q1 FY2026, down 8.5% from a year earlier and down 2.4% from the prior quarter. Over 3 fiscal years it compounded at +26.3% a year.
Context
- Total non-current liabilities amounted to 1.3% of total assets at the end of Q1 FY2026, down 0.4 pp from a year earlier.
- Total non-current liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -8.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 5.34M USD
- Year-over-year change
- -8.2%
- 4-year CAGR
- +41.1%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.34M | -8.2% |
| FY2024 | 2024-12-31 | 5.81M | -7.2% |
| FY2023 | 2023-12-31 | 6.26M | +136.2% |
| FY2022 | 2022-12-31 | 2.65M | +96.7% |
| FY2021 | 2021-12-31 | 1.35M | — |
Total Non-current Liabilities vs competitors
How TYRA compares with its peers on the latest reported figures
- TYRA's Mar 2026 total non-current liabilities of $5.21M is the 7th highest of the 11 companies compared; the peer median is $53.48M.
- Its year-over-year change of -8.5% is the 7th highest of 9, against a peer median of +22.7%.
- Total non-current liabilities amounts to 1.3% of total assets for TYRA, versus a peer median of 18.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $443.17M | +53.0% | +234.3% | 67.9% | |
| Jun 2026 | $403.88M | +94.2% | +275.6% | 54.2% | |
| Mar 2026 | $234.17M | -6.0% | -10.9% | 105.4% | |
| Mar 2026 | $100.74M | +11.9% | +16.9% | 46.2% | |
| Mar 2026 | $79.19M | -38.4% | +65.1% | 34.8% | |
| Mar 2026 | $27.78M | +33.5% | -1.3% | 2.7% | |
| Mar 2026 | $5.21M | -8.5% | +26.3% | 1.3% | |
| Mar 2026 | $3.43M | -37.6% | -21.0% | 0.8% | |
| Mar 2026 | $1.66M | +236.3% | -19.1% | 0.4% | |
| Mar 2026 | $320K | — | — | 0.1% | |
BCAXBicara Therapeutics Inc. Common Stock | Mar 2026 | $301K | — | +91.1% | 0.1% |
| Peer median (excluding TYRA) | $53.48M | +22.7% | +16.9% | 18.7% | |
Competitors are the stored peer set for TYRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 302.18M | 251.21M | 58.01M | 91.97M | 77.39M |
| Short-term Investments | 0 | 0 | 145.46M | 249.48M | 178.62M |
| Net Receivables | 0 | 0 | 0 | 2M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 6.08M | 8.2M | 4.02M | 9.45M |
| Total Current Assets | 304.06M | 257.29M | 211.67M | 347.46M | 265.45M |
| Property, Plant & Equipment (Net) | 2.09M | 3.54M | 8.15M | 7.72M | 6.89M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 555K | 5.35M | 6.03M | 8.38M | 10.27M |
| Total Non-current Assets | 2.64M | 8.89M | 14.19M | 16.1M | 17.16M |
| Total Assets | 306.7M | 266.18M | 225.86M | 363.56M | 282.61M |
| Account Payables | 599K | 1.15M | 4.66M | 590K | 1.18M |
| Short-term Debt | 0 | 0 | 0 | 412K | 472K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 5.27M | 7.14M | 10.91M |
| Total Current Liabilities | 3.62M | 5.7M | 15.33M | 14.59M | 18.09M |
| Long-term Debt | 0 | 0 | 0 | 0 | 5.34M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 367K | 169K | 46K | 3K | 0 |
| Total Non-current Liabilities | 1.35M | 2.65M | 6.26M | 5.81M | 5.34M |
| Total Liabilities | 4.96M | 8.35M | 21.6M | 20.41M | 23.43M |
| Common Stock | 4K | 4K | 4K | 5K | 5K |
| Retained Earnings | (40.37M) | (95.7M) | (164.83M) | (251.31M) | (371.26M) |
| Accumulated OCI | 0 | 0 | 381K | 770K | 393K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 301.74M | 257.83M | 204.26M | 343.15M | 259.18M |
| Total Debt | 1.18M | 2.62M | 6.5M | 6.22M | 5.81M |
| Net Debt | (301M) | (248.59M) | (51.51M) | (85.74M) | (71.58M) |
Tyra Biosciences, Inc.
NASDAQ:TYRA
Intrinsic Alpha fair value
Locked
Current Price
$19.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.